Login to Your Account



Financings Roundup

IPO Window Opening? Tesaro Prices Within Expected Range

By Peter Winter
BioWorld Insight Editor

Friday, June 29, 2012
The fact that oncology-focused biopharmaceutical company Tesaro Inc., of Waltham, Mass., completed a successful and oversubscribed initial public offering (IPO) that was within its expected price range could be a sign of better things to come in the second half of the year for biotech companies now positioned on the IPO runway.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription